Physician profile
Robert L Smith
NPI 1457370884
$5,251.60
in general payments reported to CMS, 2019-2025
39 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $179 · 2021: $947 · 2022: $779 · 2023: $1,635 · 2024: $916 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Travel and Lodging: $839 · Education: $89.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.43 |
| Travel and Lodging | $839.20 |
| Education | $89.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,268.94 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $770.69 | 2019-2023 | Lo Loestrin Fe, Orilissa, Qulipta |
| Novo Nordisk INC | $407.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $368.30 | 2021-2025 | Veozah |
| Exeltis, USA INC. | $271.69 | 2020-2022 | |
| Agile Therapeutics, INC. | $229.58 | 2021-2024 | Twirla |
| Allergan, INC. | $153.71 | 2019-2020 | |
| Myovant Sciences INC. | $148.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.34 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $134.33 | 2021-2024 | Xarelto |
| Pfizer INC. | $122.94 | 2019-2024 | |
| Lilly USA, LLC | $120.50 | 2022-2024 | Jardiance, Emgality, Zepbound |
| Mylan Pharmaceuticals INC. | $106.65 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.83 | 2019-2021 | |
| Shield Therapeutics INC | $88.29 | 2023-2025 | Accrufer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $87.93 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Medline Industries Lp | $81.46 | 2023 | |
| Vifor Pharma, INC. | $75.39 | 2024 | Veltassa |
| Coopersurgical, INC. | $73.27 | 2019-2023 | Advincula Delineator Uterine Manipulator |
| Glaxosmithkline, LLC. | $68.86 | 2021-2025 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $59.36 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $47.77 | 2024 | Myfembree |
| Evofem Biosciences, INC. | $43.82 | 2022 | |
| Amarin Pharma, INC. | $42.51 | 2021 | |
| Therapeuticsmd, INC. | $39.49 | 2019-2020 | |
| Scynexis, INC. | $31.03 | 2022 | |
| Mayne Pharma Commercial LLC | $25.48 | 2022 | |
| Dexcom, INC. | $25.34 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $22.08 | 2022 | |
| Corcept Therapeutics | $21.71 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $20.64 | 2023 | Dificid |
| Pacira Pharmaceuticals Incorporated | $15.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2023 | Seglentis, Livalo |
| Amgen INC. | $14.00 | 2021 | |
| Avion Pharmaceuticals | $11.04 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.04 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.